ABSTRACT
BACKGROUND: Gastric cancer, as one of the increasingly common malignancies, has experienced high morbidity throughout many countries at present. Currently, chemotherapy regimen with more efficacy and safety for advanced gastric cancer (AGC) is needed. We aimed to assess the clinical efficacy and safety of S-1 combined with paclitaxel (PTX) for AGC by performing a systematic review and meta-analysis of the published studies. METHOD: All published randomized controlled trials (RCTs) of S-1 combined with PTX for AGC were searched. Studies that included patients with locally advanced or metastases' gastric cancers were included. We searched the databases included Cochrane Library of Clinical Comparative Trials, MEDLINE, Embase, American Society of Clinical Oncology meeting abstracts and China National Knowledge Internet (CNKI) from 2000 to 2018. We searched the database up to January 2018. The first endpoint was overall survival (OS). Other endpoints were progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR). Safety analyses were also performed. RESULTS: A total of 7 trials (including 1407 patients, 711 patients in intervention group and 696 patients in control group) were included in the present analysis. S-1 combined with PTX significantly improved the OS [HRâ¯=â¯0.78, 95% CI: 0.60-0.97, Pâ¯=â¯0.000],PFS [HRâ¯=â¯0.70, 95% CI: 0.55-0.85, Pâ¯=â¯0.000], ORR [RRâ¯=â¯1.30, 95%CI: 1.05-1.60, Pâ¯=â¯0.017] and DCR [RRâ¯=â¯1.15, 95%CI: 1.04-1.27, Pâ¯=â¯0.008] of patients with AGC. The grade 3 or 4 haematological and non-hematologic toxicities were anemia [RRâ¯=â¯1.71, 95% CI: 1.04-2.79, Pâ¯=â¯0.03], neutropenia [RRâ¯=â¯1.65, 95% CI: 1.32-2.06, Pâ¯<â¯0.0001] and anorexia [RRâ¯=â¯1.66, 95% CI: 1.05-2.64, Pâ¯=â¯0.03] respectively. CONCLUSION: S-1 combined with PTX may be a good choice for patients with AGC. S-1 plus PTX experienced more efficacy and safety when compared with S-1 alone or S-1 plus other drugs.
